Lucid Diagnostics (LUCD) Hisse Özeti
Lucid Diagnostics Inc. Amerika Birleşik Devletleri'nde ticari aşamada bir tıbbi teşhis teknolojisi şirketi olarak faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 0/6 |
| Gelecekteki Büyüme | 2/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 5/6 |
| Temettüler | 0/6 |
LUCD Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
IN
Community Contributor
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.
View narrativeUS$5
FV
80.0% değerinin altında içsel indirim94
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
Lucid Diagnostics Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$1.00 |
| 52 Haftanın En Yüksek Seviyesi | US$1.63 |
| 52 Haftanın En Düşük Seviyesi | US$0.90 |
| Beta | 1.07 |
| 1 Aylık Değişim | 4.09% |
| 3 Aylık Değişim | -29.08% |
| 1 Yıllık Değişim | -14.53% |
| 3 Yıllık Değişim | -27.54% |
| 5 Yıllık Değişim | n/a |
| Halka arzdan bu yana değişim | -91.50% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jul 07
LUCD: Higher Future P/E Assumptions Will Reflect Medicare Reimbursement Upside Potential
Analysts have lowered their price target on Lucid Diagnostics to $2 from $3, reflecting updated assumptions on revenue growth, profitability, and discount rates following recent quarterly results and continued uncertainty around Medicare coverage. Analyst Commentary Recent research on Lucid Diagnostics highlights a more cautious stance from several bearish analysts following the latest quarterly update.
Anlatı Güncellemesi • Jun 23
LUCD: Medicare Coverage Decision Will Drive Constructive Future Repricing Potential
Lucid Diagnostics’ analyst price target has moved in a mixed fashion recently, with one firm cutting its target to $2 from $3 after a Q1 revenue miss and ongoing Medicare coverage uncertainty, while other analysts cite continued commercialization efforts as support for maintaining a constructive view on the stock. Analyst Commentary Recent Street research on Lucid Diagnostics reflects a mix of caution and optimism, with some analysts trimming price targets after the Q1 revenue shortfall, while others highlight ongoing commercialization work and the potential impact of future Medicare coverage decisions on valuation.Anlatı Güncellemesi • Jun 04
LUCD: Medicare Coverage Decision And Commercial Ramp Will Drive Future Repricing
Analysts have adjusted their views on Lucid Diagnostics with a lower blended price target, reflecting a mix of reduced expectations, such as Maxim's cut to $2 from $3 after a Q1 revenue miss and ongoing uncertainty around Medicare coverage, balanced against support for the company's continued commercialization efforts. Analyst Commentary Bullish analysts continue to frame Lucid Diagnostics as an early commercial story where execution on test adoption and payer coverage could be important drivers for the stock.Recent updates
Anlatı Güncellemesi • Jul 07
LUCD: Higher Future P/E Assumptions Will Reflect Medicare Reimbursement Upside Potential
Analysts have lowered their price target on Lucid Diagnostics to $2 from $3, reflecting updated assumptions on revenue growth, profitability, and discount rates following recent quarterly results and continued uncertainty around Medicare coverage. Analyst Commentary Recent research on Lucid Diagnostics highlights a more cautious stance from several bearish analysts following the latest quarterly update.Anlatı Güncellemesi • Jun 23
LUCD: Medicare Coverage Decision Will Drive Constructive Future Repricing Potential
Lucid Diagnostics’ analyst price target has moved in a mixed fashion recently, with one firm cutting its target to $2 from $3 after a Q1 revenue miss and ongoing Medicare coverage uncertainty, while other analysts cite continued commercialization efforts as support for maintaining a constructive view on the stock. Analyst Commentary Recent Street research on Lucid Diagnostics reflects a mix of caution and optimism, with some analysts trimming price targets after the Q1 revenue shortfall, while others highlight ongoing commercialization work and the potential impact of future Medicare coverage decisions on valuation.Anlatı Güncellemesi • Jun 04
LUCD: Medicare Coverage Decision And Commercial Ramp Will Drive Future Repricing
Analysts have adjusted their views on Lucid Diagnostics with a lower blended price target, reflecting a mix of reduced expectations, such as Maxim's cut to $2 from $3 after a Q1 revenue miss and ongoing uncertainty around Medicare coverage, balanced against support for the company's continued commercialization efforts. Analyst Commentary Bullish analysts continue to frame Lucid Diagnostics as an early commercial story where execution on test adoption and payer coverage could be important drivers for the stock.Anlatı Güncellemesi • Apr 25
LUCD: Higher Future P/E Assumptions Will Support Upside Despite Execution Risks
Analysts have lifted their price target on Lucid Diagnostics by $0.75, citing updated assumptions around the discount rate, revenue growth, profit margins, and a higher future P/E multiple as the key drivers of the change. Analyst Commentary While the higher price target reflects updated modeling assumptions, bearish analysts still flag several areas of concern that readers should keep in mind when thinking about Lucid Diagnostics.Anlatı Güncellemesi • Apr 11
LUCD: Revised Outlook Suggests VA Contract Will Support Future Repricing
Analysts have adjusted their price target on Lucid Diagnostics from $8.25 to $9.00, reflecting updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations. Analyst Commentary Recent research highlights a constructive tone around Lucid Diagnostics, with bullish analysts pointing to updated assumptions on revenue growth, profitability, discount rate, and future P/E expectations as key reasons behind the higher price target of US$9.00.
Yeni Anlatı • Apr 01
Poised for success
Lucid Diagnostics' EsoGuard is a novel screening tool for esophageal cancer. It is relatively non-invasive and may become widely accepted soon.Anlatı Güncellemesi • Mar 27
LUCD: VA Contract Will Drive Broader Future Adoption And Repricing
Analysts have raised their price target for Lucid Diagnostics to $8.25. This reflects updated views on fair value, discount rate, revenue growth, profit margin, and a very high anticipated future P/E multiple.Anlatı Güncellemesi • Mar 12
LUCD: VA Contract Will Expand Screening Access And Support Future Upside
Analysts have modestly adjusted their price target for Lucid Diagnostics to reflect slightly updated assumptions on discount rate, revenue growth, profit margin, and future P/E, while keeping their overall fair value estimate steady at $2.50. What's in the News Lucid Diagnostics received a contract from the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, aimed at expanding access to esophageal precancer testing across the VA healthcare system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).Anlatı Güncellemesi • Feb 26
LUCD: VA Screening Access And Safety Data Will Support Future Upside
Analysts kept their Lucid Diagnostics price target steady at $2.50, pointing to largely unchanged fair value and P/E assumptions, with only small tweaks to the discount rate, revenue growth, and profit margin inputs behind their models. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, making the test available across the VA's national integrated healthcare system that serves more than 9 million enrolled veterans each year (Key Developments).Anlatı Güncellemesi • Feb 11
LUCD: VA Screening Contract And Real World Data Will Support Future Upside
Analysts have modestly revised their price target on Lucid Diagnostics, citing adjusted assumptions for the discount rate, revenue growth, profit margin, and future P/E that maintain a fair value estimate of $2.50. What's in the News Lucid Diagnostics secured a U.S. Department of Veterans Affairs contract for its EsoGuard Esophageal DNA Test, giving VA hospitals and facilities nationwide a single procurement framework and expanding access across the system that serves more than nine million enrolled veterans annually (Key Developments).Anlatı Güncellemesi • Jan 27
LUCD: VA Contract And Real World Screening Data Will Support Future Upside
Analysts have adjusted their price target for Lucid Diagnostics slightly, maintaining fair value at about US$2.50 while fine tuning assumptions on the discount rate, revenue growth, profit margins and future P/E to reflect updated views on the company’s risk profile and earnings power. What's in the News Lucid Diagnostics secured a contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access to esophageal precancer testing across the VA system, which serves more than 9,000,000 enrolled veterans annually (Key Developments).Seeking Alpha • Jan 26
Lucid Diagnostics: Green Flags, But Dilution And Friction Keep Me Neutral
Summary Lucid offers an office-based esophageal precancer screening. The FDA cleared EsoCheck sampling plus EsoGuard NGS epigenetic assay to triage EGD referrals. In my view, their core upside hinges on broader Medicare coverage. The recent CAC support and 45-day notice suggest improving odds on this front. LUCD’s Q3 2025 showed 2,841 tests and $7.1 million in pro-forma revenues billed. But, only $1.2 million could be conservatively recognized. So, there’s still considerable friction for LUCD’s underlying business. Fortunately, real-world evidence looks promising, and the VA FSS contract is a green flag. I think LUCD is heading in the right direction. But it still sports a premium valuation despite its several uncertainties and dilution risks. So I remain neutral on the stock. Read the full article on Seeking AlphaAnlatı Güncellemesi • Jan 13
LUCD: Real World Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have slightly reduced their price target on Lucid Diagnostics, citing updated assumptions that keep fair value steady at $2.50 while reflecting small adjustments to the discount rate, revenue growth, profit margin and future P/E expectations. What's in the News New real world data on Lucid Diagnostics EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device cover 11,991 at risk patients over 18 months of routine clinical use between January 2023 and June 2024 (medRxiv preprint).Anlatı Güncellemesi • Dec 14
LUCD: New Screening Data Will Support Stronger Long-Term Profit Potential
Analysts have raised their price target on Lucid Diagnostics by approximately 25 percent to reflect higher projected revenue growth, slightly improved long term profitability, and a modestly higher valuation multiple despite a small uptick in the assumed discount rate. What's in the News Reported new 18-month real-world data in 11,991 at-risk patients using EsoGuard and EsoCheck for nonendoscopic Barrett's esophagus screening, supporting their utility as scalable, noninvasive tools in routine clinical practice (company announcement) Study authors highlighted excellent safety and tolerability, with EsoCheck achieving a 95% technical success rate, most procedures completed in under two minutes, and no serious adverse events (company announcement) Most patients in the analysis met U.S. gastroenterology society guideline criteria for Barrett's esophagus screening, indicating appropriate physician adoption of EsoGuard and EsoCheck (company announcement) Valuation Changes Fair Value: risen moderately from 2.0x to 2.5x, reflecting a higher implied valuation multiple on forward fundamentals.Analiz Makalesi • Dec 13
Is Lucid Diagnostics (NASDAQ:LUCD) Using Too Much Debt?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Yeni Anlatı • Apr 12
Expanded Reimbursement And Cash-Pay Programs Will Open Future Markets
Expanding reimbursement coverage and leveraging NCCN guidelines are strategies expected to enhance revenue and credibility with payers.Analiz Makalesi • May 09
We're A Little Worried About Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Analiz Makalesi • Dec 15
Lucid Diagnostics (NASDAQ:LUCD) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Seeking Alpha • Aug 11
Lucid Diagnostics launches stage II lucid test center in California, Texas, Florida, and Ohio
Lucid Diagnostics (NASDAQ:LUCD) announced on Thursday that its subsidiary, LucidDx Labs, has launched four new Lucid Test Centers in California, Texas, Florida and Ohio. Patients in the metropolitan areas with chronic heartburn can order from their own physician or from a telemedicine physician and can now undergo a brief, non-invasive, office-based test to detect esophageal precancer before it progresses to deadly esophageal cancer, using Lucid’s EsoGuard DNA Esophageal Test. The test centers are staffed with Lucid-employed nurse practitioners who use EsoCheck to collect surface esophageal cells which are sent to LucidDx Labs for EsoGuard testing. (LUCD) has risen ~2% premarket.Analiz Makalesi • Jul 07
We're Keeping An Eye On Lucid Diagnostics' (NASDAQ:LUCD) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Hissedar Getirileri
| LUCD | US Medical Equipment | US Pazar | |
|---|---|---|---|
| 7D | -2.9% | -6.0% | 0.2% |
| 1Y | -14.5% | -21.7% | 19.6% |
Getiri vs. Endüstri: LUCD geçen yıl % -21.7 oranında getiri sağlayan US Medical Equipment sektörünü aştı.
Getiri vs Piyasa: LUCD geçen yıl % 19.6 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| LUCD volatility | |
|---|---|
| LUCD Average Weekly Movement | 8.9% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: LUCD son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: LUCD 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2018 | 82 | Lishan Aklog | www.luciddx.com |
Lucid Diagnostics Inc. Amerika Birleşik Devletleri'nde ticari aşamada bir tıbbi teşhis teknolojisi şirketi olarak faaliyet göstermektedir. Başta yüksek derecede ölümcül özofagus adenokarsinomu olmak üzere özofagus prekanseri ve kanseri gelişme riski taşıyan gastroözofageal reflü hastalığı (GÖRH) olan hastalara odaklanmaktadır. Şirketin amiral gemisi ürünü olan EsoGuard Özofagus DNA Testi, risk altındaki GÖRH hastalarında özofagus prekanserinin erken tespiti yoluyla EAK ölümlerini önlemeyi amaçlayan bir test aracı olan EsoCheck Özofagus Hücresi toplama cihazı ile toplanan örnekler üzerinde gerçekleştirilir.
Lucid Diagnostics Inc. Temel Bilgiler Özeti
| LUCD temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$189.07m |
| Kazançlar(TTM) | -US$58.18m |
| Gelir(TTM) | US$5.13m |
37.2x
P/S Oranı-3.3x
F/K OranıLUCD aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| LUCD gelir tablosu (TTM) | |
|---|---|
| Gelir | US$5.13m |
| Gelir Maliyeti | US$6.74m |
| Brüt Kâr | -US$1.61m |
| Diğer Giderler | US$56.57m |
| Kazançlar | -US$58.18m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -0.30 |
| Brüt Marj | -31.36% |
| Net Kâr Marjı | -1,133.21% |
| Borç/Özkaynak Oranı | 630.0% |
LUCD uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/14 20:18 |
| Gün Sonu Hisse Fiyatı | 2026/07/14 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Lucid Diagnostics Inc. 5 Bu analistlerden 5, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Mark Massaro | BTIG |
| Kyle Mikson | Canaccord Genuity |